Ownership history in Resolute Capital Asset Partners LLC Β· 16 quarters on record
This page tracks every 13F SEC filing in which Resolute Capital Asset Partners LLC reported a position in ASCENDIS PHARMA A/S (ASND). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π Resolute Capital Asset Partners LLC outperformed the S&P 500 by +8.6% annually on this ASND position. Timing score: 40% (4/10 decisions correct). Average cost basis: $144.67. Maximum drawdown during holding period: β26.9%.
π₯ Exceptional β beat the S&P 500 by 8.6% per year on this position.
11 quarters analyzed
β οΈ Poor timing β buys often preceded drops, trims preceded rallies.
4 of 10 add/trim decisions correct
Best entry: $103.26 (2022 Q3) Β· Worst: $198.81 (2025 Q3)
πͺ Held through 2 major drawdowns (>20%).
8 adds Β· 3 trims. Bought during 1 of 5 down-price quarters. π Consistently bullish β fund kept accumulating this position.
π Resolute Capital Asset Partners LLC has been actively increasing its ASND allocation β a bullish signal from insiders.
Currently 9.13% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size